Yan Huo , Zhe Zhang , Suzhen Dong , Yijie Du , Mingliang Ma
{"title":"脑卒中多肽药物的临床研究进展。","authors":"Yan Huo , Zhe Zhang , Suzhen Dong , Yijie Du , Mingliang Ma","doi":"10.1016/j.bbadis.2025.167970","DOIUrl":null,"url":null,"abstract":"<div><div>Stroke remains a leading cause of death and disability globally, with limited treatment options currently available. Fortunately, peptide drugs have emerged as promising candidates for treating central nervous system disorders, including stroke. They offer high specificity, low toxicity, and efficient blood-brain barrier penetration, demonstrating significant therapeutic potential. This review systematically introduces several promising peptide drugs, analyzing their mechanisms, therapeutic efficacy in clinical trials, and potential applications. It also addresses critical challenges in peptide drug development for stroke therapy, such as optimizing dosing strategies, enhancing stability, and improving delivery systems. The analysis of current clinical evidence suggests that peptide-based therapeutics represent a promising frontier in stroke treatment, potentially offering new therapeutic options for patients. This comprehensive review not only highlights the current status of peptide drug development but also provides insights into future directions for advancing stroke therapy.</div></div>","PeriodicalId":8821,"journal":{"name":"Biochimica et biophysica acta. Molecular basis of disease","volume":"1871 7","pages":"Article 167970"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in clinical studies of peptide drugs in stroke disease\",\"authors\":\"Yan Huo , Zhe Zhang , Suzhen Dong , Yijie Du , Mingliang Ma\",\"doi\":\"10.1016/j.bbadis.2025.167970\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Stroke remains a leading cause of death and disability globally, with limited treatment options currently available. Fortunately, peptide drugs have emerged as promising candidates for treating central nervous system disorders, including stroke. They offer high specificity, low toxicity, and efficient blood-brain barrier penetration, demonstrating significant therapeutic potential. This review systematically introduces several promising peptide drugs, analyzing their mechanisms, therapeutic efficacy in clinical trials, and potential applications. It also addresses critical challenges in peptide drug development for stroke therapy, such as optimizing dosing strategies, enhancing stability, and improving delivery systems. The analysis of current clinical evidence suggests that peptide-based therapeutics represent a promising frontier in stroke treatment, potentially offering new therapeutic options for patients. This comprehensive review not only highlights the current status of peptide drug development but also provides insights into future directions for advancing stroke therapy.</div></div>\",\"PeriodicalId\":8821,\"journal\":{\"name\":\"Biochimica et biophysica acta. Molecular basis of disease\",\"volume\":\"1871 7\",\"pages\":\"Article 167970\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochimica et biophysica acta. Molecular basis of disease\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0925443925003187\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Molecular basis of disease","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0925443925003187","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Advances in clinical studies of peptide drugs in stroke disease
Stroke remains a leading cause of death and disability globally, with limited treatment options currently available. Fortunately, peptide drugs have emerged as promising candidates for treating central nervous system disorders, including stroke. They offer high specificity, low toxicity, and efficient blood-brain barrier penetration, demonstrating significant therapeutic potential. This review systematically introduces several promising peptide drugs, analyzing their mechanisms, therapeutic efficacy in clinical trials, and potential applications. It also addresses critical challenges in peptide drug development for stroke therapy, such as optimizing dosing strategies, enhancing stability, and improving delivery systems. The analysis of current clinical evidence suggests that peptide-based therapeutics represent a promising frontier in stroke treatment, potentially offering new therapeutic options for patients. This comprehensive review not only highlights the current status of peptide drug development but also provides insights into future directions for advancing stroke therapy.
期刊介绍:
BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The submission of uninvited reviews to BBA - Molecular Basis of Disease is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.